Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period

Bone

Volumn 64, Issue , 2014, Pages 314-325

  Boyce, Rogely W ^a   Varela, Aurore ^b   Chouinard, Luc ^b   Bussiere, Jeanine L ^a   Chellman, Gary J ^b   Ominsky, Michael S ^a   Pyrah, Ian T ^a  

^a AMGEN INC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Brittle bone; Denosumab; Osteopetrosis; Pre postnatal toxicity

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; DRUG ANTIBODY; OSTEOCALCIN; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ADULT; ALBERS SCHOENBERG DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE DEVELOPMENT; BONE GROWTH; BONE LENGTH; BONE MASS; BONE RADIOGRAPHY; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CONTROLLED STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); DEVELOPMENTAL TOXICITY; ENCHONDRAL OSSIFICATION; FEMALE; FRAGILITY FRACTURE; GROWTH PLATE; HISTOPATHOLOGY; INFANT; MACACA FASCICULARIS; MOUTH EXAMINATION; NONHUMAN; PERINATAL PERIOD; PHENOTYPE; PRENATAL DRUG EXPOSURE; TOOTH ERUPTION; TOOTH MALFORMATION; ANIMAL; COMPUTER ASSISTED TOMOGRAPHY; IMMUNOLOGY; OSTEOCLAST; PATHOLOGY; PREGNANCY; PRENATAL EXPOSURE; RADIOGRAPHY; TOXICITY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE REMODELING; FEMALE; MACACA FASCICULARIS; OSTEOCLASTS; OSTEOPETROSIS; PHENOTYPE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; TOMOGRAPHY, X-RAY COMPUTED; TOOTH ERUPTION;

EID: 84901026428     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.04.002     Document Type: Article

References (45)

1. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
2. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999, 13:2412-2424.
3. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423:337-342.
4. Kearns A.E., Khosla S., Kostenuik P.J. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008, 29:155-192.
5. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
6. Marks S.C. Tooth eruption depends on bone resorption: experimental evidence from osteopetrotic (ia) rats. Metab Bone Dis Relat Res 1981, 3:107-115.
7. Wise G.E. Cellular and molecular basis of tooth eruption. Orthod Craniofac Res 2009, 12:67-73.
8. Johnson R.S., Spiegelman B.M., Papaioannou V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 1992, 71:577-586.
9. Ida-Yonemochi H., Noda T., Shimokawa H., Saku T. Disturbed tooth eruption in osteopetrotic (op/op) mice: histopathogenesis of tooth malformation and odontomas. J Oral Pathol Med 2002, 31:361-373.
10. XGEVA® Prescribing Information Accessed at. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125320s0085lbl.pdf.
11. Prolia® Prescribing Information Accessed at. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125320s0051lbl.pdf.
12. Kostenuik P.J., Smith S.Y., Jolette J., Schroeder J., Pyrah I., Ominsky M.S. Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody. Bone 2011, 49:151-161.
13. Bussiere J.L., Pyrah I. A 6/12-month toxicity study of denosumab in cynomolgus monkeys. J Bone Miner Res 2012, 27(Suppl. 1):S466.
14. Bussiere J.L., Pyrah I., Boyce R., Branstetter D., Loomis M., Andrews-Cleavenger D., et al. Reproductive toxicity of denosumab in cynomolgus monkeys. Reprod Toxicol 2013, 42:27-40.
15. Turner C.H., Burr D.B. Basic biomechanical measurements of bone: a tutorial. Bone 1993, 14:595-608.
16. Smith B.H., Crummett T.L., Brandt K.L. Ages of eruption of primate teeth: a compendium for aging individuals and comparing life histories. Am J Phys Anthropol 1994, 37:177-231.
17. Jee W.S.S. The skeletal tissues 1983, Elsevier Science Publishing, Inc, New York. 5th ed.
18. Felix R., Hofstetter W., Cecchini M.G. Recent developments in the understanding of the pathophysiology of osteopetrosis. Eur J Endocrinol 1996, 134:143-156.
19. Schenk R., Merz W.A., Muhlbauer R., Russell R.G., Fleisch H. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973, 11:196-214.
20. Pataki A., Muller K., Green J.R., Ma Y.F., Li Q.N., Jee W.S. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec 1997, 249:458-468.
21. Smith E.J., Little D.G., Briody J.N., McEvoy A., Smith N.C., Eisman J.A., et al. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits. J Bone Miner Res 2005, 20:1731-1741.
22. Whyte M.P., Wenkert D., Clements K.L., McAlister W.H., Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 2003, 349:457-463.
23. Tolar J., Teitelbaum S.L., Orchard P.J. Osteopetrosis. N Engl J Med 2004, 351:2839-2849.
24. Del Fattore A., Cappariello A., Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone 2008, 42:19-29.
25. Pentsuk N., van der Laan J.W. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 2009, 86:328-344.
26. Patlas N., Golomb G., Yaffe P., Pinto T., Breuer E., Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999, 60:68-73.
27. Frost H.M. Skeletal structural adaptations to mechanical usage (SATMU): 2. Redefining Wolff's law: the remodeling problem. Anat Rec 1990, 226:414-422.
28. Tuukkanen J., Koivukangas A., Jamsa T., Sundquist K., Mackay C.A., Marks S.C. Mineral density and bone strength are dissociated in long bones of rat osteopetrotic mutations. J Bone Miner Res 2000, 15:1905-1911.
29. Souraty N., Noun P., Djambas-Khayat C., Chouery E., Pangrazio A., Villa A., et al. Molecular study of six families originating from the Middle-East and presenting with autosomal recessive osteopetrosis. Eur J Med Genet 2007, 50:188-199.
30. Sobacchi C., Schulz A., Coxon F.P., Villa A., Helfrich M.H. Osteopetrosis: genetics, treatment and new insights into osteoclast function. Nat Rev Endocrinol 2013, 9:522-536.
31. Kamoun-Goldrat A., Ginisty D., Le Merrer M. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 2008, 116:195-198.
32. Odgren P.R., Philbrick W.M., Gartland A. Perspective. Osteoclastogenesis and growth plate chondrocyte differentiation: emergence of convergence. Crit Rev Eukaryot Gene Expr 2003, 13:181-193.
33. Wang B., Jin H., Zhu M., Li J., Zhao L., Zhang Y., et al. Chondrocyte β-catenin signaling regulates postnatal bone remodeling through modulation of osteoclast formation in a murine model. Arthritis Rheumatol 2014, 66:107-120.
34. Kishimoto K., Kitazawa R., Kurosaka M., Maeda S., Kitazawa S. Expression profile of genes related to osteoclastogenesis in mouse growth plate and articular cartilage. Histochem Cell Biol 2006, 125:593-602.
35. Ikeda T., Utsuyama M., Hirokawa K. Expression profiles of receptor activator of nuclear factor kappaB ligand, receptor activator of nuclear factor kappaB, and osteoprotegerin messenger RNA in aged and ovariectomized rat bones. J Bone Miner Res 2001, 16:1416-1425.
36. Boyce B.F., Yao Z., Xing L. Osteoclasts have multiple roles in bone in addition to bone resorption. Crit Rev Eukaryot Gene Expr 2009, 19:171-180.
37. Turner C.H. Determinants of skeletal fragility and bone quality. J Musculoskelet Neuronal Interact 2002, 2:527-528.
38. Whyte M.P., McAlister W.H., Novack D.V., Clements K.L., Schoenecker P.L., Wenkert D. Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res 2008, 23:1698-1707.
39. Loria-Cortes R., Quesada-Calvo E., Cordero-Chaverri C. Osteopetrosis in children: a report of 26 cases. J Pediatr 1977, 91:43-47.
40. Yuan P., Yue Z., Sun L., Huang W., Hu B., Yang Z., et al. Novel mutation of TCIRG1 and clinical pictures of two infantile malignant osteopetrosis patients. J Bone Miner Metab 2011, 29:251-256.
41. Gerritsen E.J., Vossen J.M., van Loo I.H., Hermans J., Helfrich M.H., Griscelli C., et al. Autosomal recessive osteopetrosis: variability of findings at diagnosis and during the natural course. Pediatrics 1994, 93:247-253.
42. Whyte M.P. Osteopetrosis. Connective tissue and its heritable disorders: medical, genetic, and molecular aspects 2002, Wiley-Liss, Inc, New York. P.M. Royce, B. Steinman (Eds.).
43. Helfrich M.H., Aronson D.C., Everts V., Mieremet R.H., Gerritsen E.J., Eckhardt P.G., et al. Morphologic features of bone in human osteopetrosis. Bone 1991, 12:411-419.
44. Sobacchi C., Frattini A., Guerrini M.M., Abinun M., Pangrazio A., Susani L., et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007, 39:960-962.
45. Guerrini M.M., Sobacchi C., Cassani B., Abinun M., Kilic S.S., Pangrazio A., et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008, 83:64-76.